Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Limited reports developments around its consumer health sciences business, led by IM8, a premium health and longevity brand focused on daily nutrition and supplementation. Company updates commonly cover IM8 product lines such as Daily Ultimate Essentials, Daily Ultimate Longevity and The Beckham Stack, as well as brand partnerships across professional sports, preventive health testing and nutrition-access initiatives.
Recurring Prenetics news also includes financial results, earnings calls, revenue and profitability commentary, share repurchase activity, executive share purchases, balance-sheet positioning and capital allocation. Recent corporate updates reflect the company’s strategic focus on IM8 following divestitures and a shift away from digital-asset treasury expansion.
Prenetics (NASDAQ: PRE) reported Q2 2026 total revenue of $46.5 million, an increase of about 288% year over year, in line with guidance of $46–48 million. IM8 revenue reached $45.0 million, up roughly 359% year over year and within guidance of $44–46 million, marking the sixth consecutive record quarter.
According to Prenetics, July was IM8’s strongest month to date with $20.9 million in revenue, implying an annualized run-rate of approximately $251 million. The company raised its FY 2026 IM8 revenue guidance to $220–230 million and initiated FY 2027 IM8 revenue guidance of $400 million+. July was also the first month of positive consolidated Adjusted Free Cash Flow, which Prenetics expects to remain positive for Q3 and beyond. Financials are presented under IFRS, with certain divested businesses classified as discontinued operations and results unaudited.
MetLife (NYSE: MET) declared third-quarter 2026 preferred stock dividends on four series. Series A (MET PRA) will pay a quarterly dividend of $0.31471411 per share. Series D will pay a semi-annual dividend of $29.375 per share. Series E (MET PRE) and Series F (MET PRF) will pay quarterly dividends of $351.5625 and $296.875 per share, respectively, or $0.3515625 and $0.296875 per depositary share. All dividends are payable on September 15, 2026, to shareholders of record as of August 31, 2026.
Prenetics (NASDAQ: PRE), parent of AI-native wellness brand IM8, appointed veteran Wall Street consumer analyst Caroline Levy to its Board of Directors as an independent director. She will also join the Audit, Compensation, and Nominating and Corporate Governance committees.
Levy has over 30 years of experience covering consumer companies, including senior roles at UBS, CLSA and Macquarie, and currently serves on the Board of Celsius Holdings (NASDAQ: CELH). Prenetics also plans to report its Q2 2026 financial results on August 18, 2026, via a live webcast on StockTwits.
Prenetics (NASDAQ: PRE) will report its Q2 2026 financial results for the quarter ended June 30, 2026, before market open on Tuesday, August 18, 2026. Instead of a traditional earnings press release, Prenetics will issue a detailed shareholder letter and an investor deck on its investor relations website.
The company will host a live-streamed earnings event on Stocktwits on August 18, 2026 at 8:30 a.m. Eastern Time, featuring management commentary and Q&A. A replay will be posted on the investor relations site. Prenetics’ management will also participate in multiple investor conferences in August and September 2026 in Boston, New York City and Brooklyn.
First Horizon (NYSE: FHN) declared a quarterly cash dividend of $0.17 per share on its common stock, payable October 1, 2026 to shareholders of record on September 11, 2026.
The company also declared quarterly cash dividends on preferred securities: Series E at $1,625.00 per share or $0.40625 per FHN PRE depositary share; Series F at $1,175.00 per share or $0.29375 per FHN PRF depositary share; and Series H at $1,687.50 per share or $0.421875 per FHN PRH depositary share, each payable October 13, 2026 to holders of record on September 28, 2026. First Horizon Bank’s Class A Non-Cumulative Perpetual Preferred Stock will receive $12.82318 per share on the same dates.
Prenetics (NASDAQ: PRE), parent of AI-native wellness brand IM8, has closed a $1 billion growth financing facility with General Catalyst’s Customer Value Fund to support IM8’s marketing spend.
The CVF will fund up to 70% of IM8’s marketing on a monthly cohort basis, in exchange for a capped share of cohort-level income until a fixed multiple of deployed capital is repaid, after which all value reverts to IM8. The structure is non-dilutive, involves no equity or warrants, has no fixed maturity, covenants, or recourse beyond financed cohorts, and will be recorded as a financial liability with returns booked as interest expense.
IM8 has delivered over 50 million servings to date, about 200,000 daily, and generated preliminarily $17 million revenue in June 2026. Prenetics raised 2026 IM8 revenue guidance to $210–220 million and expects IM8 to reach $300 million annualized run-rate by year-end 2026 and exceed $400 million revenue in 2027. Management reports every $1 of customer acquisition spend has returned $1.44 in gross profit across mature cohorts.
Prenetics (NASDAQ: PRE) reported Q1 2026 revenue of $36.0 million, with IM8 contributing $33.8 million, up 23% sequentially and nearly 6x year-over-year. Gross profit was $23.3 million, with IM8 gross margin at ~64%.
Prenetics guided Q2 2026 revenue to $46–48 million and raised 2026 IM8 revenue guidance to $190–210 million. The company is debt free, has an estimated $139.7 million in cash and liquid assets, fully exited digital assets for $41.3 million, and has repurchased about $19 million of shares under a $40 million program, while still reporting a $23.1 million quarterly net loss.
Prenetics (NASDAQ: PRE), parent of health and longevity brand IM8, appointed Comfrt founder and CEO Hudson Leogrande as an independent director, effective immediately.
IM8 reached $100 million ARR in 11 months, is projected to reach $250–$300 million ARR by end-2026, and 2026 revenue guidance was raised to $190–$210 million. Three of four directors are now independent.
Prenetics (NASDAQ: PRE), parent of health and longevity brand IM8, announced a multi-year partnership with author and podcaster Jay Shetty, who becomes Global Ambassador and a shareholder.
IM8 reported preliminary Q1 2026 revenue of $33.8 million, nearly 6x year-over-year, and raised full-year 2026 revenue guidance to $190–$210 million. IM8 delivers about 150,000 servings daily across 43 countries, with over 60% of revenue generated outside the United States. May 2026 monthly revenue of approximately $15.5 million implies roughly $186 million in annualized recurring revenue.
MetLife (NYSE: MET) declared second quarter 2026 preferred stock dividends on three series. Holders of Series A (MET PRA) will receive $0.31190376 per share. Series E (MET PRE) depositary shares pay $0.3515625 each, and Series F (MET PRF) depositary shares pay $0.296875 each.
All dividends are payable June 15, 2026, to shareholders of record as of May 29, 2026.